STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Starpharma receives DEP milestone from AstraZeneca		02/06/17	172.59KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	28/04/17	120.37KB	Share
SPL	AstraZeneca DEP candidate advance triggers milestone to SPL	PRICE SENSITIVE	20/04/17	91.82KB	Share
SPL	Ansell launches VivaGel condom in Canada	PRICE SENSITIVE	12/04/17	65.41KB	Share
SPL	VivaGel BV phase 3 trials for prevention of BV completed	PRICE SENSITIVE	30/03/17	338.32KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	27/02/17	628.3KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	31/01/17	119.52KB	Share
SPL	Appendix 3B		25/01/17	114.1KB	Share
SPL	Shareholder Update January 2017	PRICE SENSITIVE	19/01/17	751.87KB	Share
SPL	VivaGel BV granted QIDP and Fast Track designation by US FDA	PRICE SENSITIVE	12/01/17	89.15KB	Share
SPL	Starpharma receives $3.5M R&D tax incentive refund	PRICE SENSITIVE	22/12/16	94.7KB	Share
SPL	Change in Director's Interest Notice - J Fairley		05/12/16	73.58KB	Share
SPL	Appendix 3B		05/12/16	115.28KB	Share
SPL	Change in Director's Interest Notice - R Thomas		05/12/16	74.47KB	Share
SPL	2016 AGM Results		29/11/16	100.62KB	Share
SPL	AGM - Chairman address and CEO presentation		29/11/16	10.17MB	Share
SPL	Starpharma signs license for VivaGel Condom in Iran	PRICE SENSITIVE	28/11/16	95.11KB	Share
SPL	Starpharma to present at Bio-Europe conference		08/11/16	94.13KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report-SPL.AX	PRICE SENSITIVE	28/10/16	296.3KB	Share
SPL	Additional Priostar Glyphosate Patent Allowed in US-SPL.AX	PRICE SENSITIVE	28/10/16	175.55KB	Share
SPL	Starpharma to present at US Drug Delivery Conference-SPL.AX		26/10/16	86.37KB	Share
SPL	Notice of Annual General Meeting/Proxy Form-SPL.AX		26/10/16	512.22KB	Share
SPL	Starpharma to present at ASX Spotlight in Asia-SPL.AX		25/10/16	174.71KB	Share
SPL	Change in Director's Interest Notice - R Thomas-SPL.AX		17/10/16	74.34KB	Share
SPL	Change in Director's Interest Notice - J Fairley-SPL.AX		13/10/16	71.85KB	Share
SPL	Appendix 3B-SPL.AX		13/10/16	114.37KB	Share
SPL	Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX	PRICE SENSITIVE	13/10/16	102.91KB	Share
SPL	Change in Director's Interest Notice - J Fairley-SPL.AX		07/10/16	71.32KB	Share
SPL	Appendix 3B-SPL.AX		07/10/16	149.9KB	Share
SPL	Notification of AGM date-SPL.AX		03/10/16	92.26KB	Share
SPL	Change in Director's Interest Notice - R Thomas-SPL.AX		19/09/16	74.33KB	Share
SPL	Change in substantial holding-SPL.AX		14/09/16	151.52KB	Share
SPL	VivaGel condom receives regulatory approval in Canada-SPL.AX	PRICE SENSITIVE	13/09/16	924.91KB	Share
SPL	Appendix 4E - Correction to NTA Backing-SPL.AX		31/08/16	193.1KB	Share
SPL	Starpharma Highlights of FY2016 Presentation-SPL.AX		30/08/16	1.5MB	Share
SPL	Appendix 4G - Corporate Governance Statement-SPL.AX		29/08/16	145.91KB	Share
SPL	Annual report and full year financial results-SPL.AX	PRICE SENSITIVE	29/08/16	2.79MB	Share
SPL	New DEP drug delivery program initiated with AstraZeneca-SPL.AX	PRICE SENSITIVE	28/07/16	81.78KB	Share
SPL	Starpharma signs license for a VivaGel condom in China-SPL.AX	PRICE SENSITIVE	21/07/16	118.11KB	Share
SPL	Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX	PRICE SENSITIVE	14/07/16	115.75KB	Share
SPL	Change in substantial holding-SPL.AX		14/06/16	219.1KB	Share
SPL	Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX	PRICE SENSITIVE	25/05/16	168.89KB	Share
SPL	Change in Director's Interest Notice - R Thomas-SPL.AX		19/05/16	73.42KB	Share
SPL	Starpharma to present at ASX CEO Session-SPL.AX		17/05/16	80.32KB	Share
SPL	Australian Olympic Team taking Dual Protect VivaGel Condoms,ANN-SPL.AX		16/05/16	129.83KB	Share
SPL	VivaGel active against Zika virus-SPL.AX	PRICE SENSITIVE	05/05/16	97.19KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report-SPL.AX	PRICE SENSITIVE	28/04/16	210.3KB	Share
SPL	Shareholder Update April 2016-SPL.AX		13/04/16	1.31MB	Share
SPL	Starpharma to present at Bio-Europe conference-SPL.AX		05/04/16	79.83KB	Share
SPL	DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX	PRICE SENSITIVE	04/04/16	173.5KB	Share
SPL	Adama Licenses Starpharma's Priostar for Novel 2,4-D	PRICE SENSITIVE	17/03/16	113.63KB	Share
SPL	Starpharma licences VivaGel BV to Aspen for ANZ	PRICE SENSITIVE	04/03/16	171.35KB	Share
SPL	Change in substantial holding		24/02/16	189.21KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	17/02/16	608.58KB	Share
SPL	Targeted DEP shows sustained superior performance	PRICE SENSITIVE	02/02/16	263.74KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	28/01/16	159.74KB	Share
SPL	Change in Director's Interest Notice - Z Peach		27/01/16	163.51KB	Share
SPL	Change in Director's Interest Notice - P Turvey		27/01/16	162.17KB	Share
SPL	Change in Director's Interest Notice - J Fairley		27/01/16	178.01KB	Share
SPL	Change in Director's Interest Notice - R Thomas		27/01/16	163.94KB	Share
SPL	Appendix 3B		25/01/16	153.88KB	Share
SPL	Appendix 3B - SPP		22/01/16	149.44KB	Share
SPL	Starpharma raises $1.9M under Share Purchase Plan	PRICE SENSITIVE	20/01/16	91.88KB	Share
SPL	Change in Director's Interest Notice - R Thomas		22/12/15	163.61KB	Share
SPL	Change in substantial holding		18/12/15	145.12KB	Share
SPL	Share Purchase Plan Offer Documents		16/12/15	657.76KB	Share
SPL	Cleansing Statement		16/12/15	289.67KB	Share
SPL	Appendix 3B - Share Placement		16/12/15	258.66KB	Share
SPL	Starpharma signs MOU for VivaGel condom in China	PRICE SENSITIVE	16/12/15	220.91KB	Share
SPL	Change in substantial holding		15/12/15	197.85KB	Share
SPL	Starpharma completes A$32 million placement	PRICE SENSITIVE	09/12/15	88.92KB	Share
SPL	Trading Halt	PRICE SENSITIVE	07/12/15	285.04KB	Share
SPL	Change in Director's Interest Notice - J Fairley		04/12/15	179.89KB	Share
SPL	Appendix 3B		04/12/15	273.29KB	Share
SPL	Second DEP candidate selected by AstraZeneca		02/12/15	79.06KB	Share
SPL	Retirement of Director Peter Jenkins and Appendix 3Z		19/11/15	289.4KB	Share
SPL	2015 AGM results		19/11/15	141.22KB	Share
SPL	AGM - Chair address and CEO presentation		19/11/15	1.75MB	Share
SPL	DEP outperforms leading treatments in ovarian cancer model	PRICE SENSITIVE	16/11/15	302.61KB	Share
SPL	Starpharma receives $3.4M R&D tax incentive	PRICE SENSITIVE	12/11/15	124.55KB	Share
SPL	Starpharma to present at BioEurope conference		04/11/15	96.89KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/10/15	136.6KB	Share
SPL	Shareholder Update October 2015		29/10/15	994.45KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		16/10/15	286.86KB	Share
SPL	Additional US Patent Granted for VivaGel BV	PRICE SENSITIVE	14/10/15	122.21KB	Share
SPL	Change in Director's Interest Notice - J Fairley		09/10/15	179.13KB	Share
SPL	Appendix 3B		09/10/15	155.34KB	Share
SPL	OTCQX Life Sciences Presentation		01/10/15	3.16MB	Share
SPL	Appendix 3B		28/09/15	256.02KB	Share
SPL	Change in Director's Interest Notice - R Thomas		28/09/15	71.66KB	Share
SPL	EU Marketing Approval Granted for VivaGel BV	PRICE SENSITIVE	24/09/15	124.11KB	Share
SPL	Date of Annual General Meeting		21/09/15	92.19KB	Share
SPL	Change in Director's Interest Notice - R Hazleton		21/09/15	163.6KB	Share
SPL	Change in Director's Interest Notice - P Turvey		10/09/15	227.66KB	Share
SPL	Change in Director's Interest Notice - Z Peach		09/09/15	226.89KB	Share
SPL	Change in Director's Interest Notice - J Fairley		09/09/15	228.52KB	Share
SPL	Change in Director's Interest Notice - R Thomas		09/09/15	227.65KB	Share
SPL	Drug delivery license with AstraZeneca conference call		07/09/15	91.45KB	Share
SPL	Starpharma signs drug delivery license with AstraZeneca	PRICE SENSITIVE	07/09/15	142.54KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	21/08/15	2.5MB	Share

SPL Starpharma receives DEP milestone from AstraZeneca
02/06/17		172.59KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
28/04/17	PRICE SENSITIVE	120.37KB	Share
SPL AstraZeneca DEP candidate advance triggers milestone to SPL
20/04/17	PRICE SENSITIVE	91.82KB	Share
SPL Ansell launches VivaGel condom in Canada
12/04/17	PRICE SENSITIVE	65.41KB	Share
SPL VivaGel BV phase 3 trials for prevention of BV completed
30/03/17	PRICE SENSITIVE	338.32KB	Share
SPL Interim Report and Half-Year Financial Results
27/02/17	PRICE SENSITIVE	628.3KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
31/01/17	PRICE SENSITIVE	119.52KB	Share
SPL Appendix 3B
25/01/17		114.1KB	Share
SPL Shareholder Update January 2017
19/01/17	PRICE SENSITIVE	751.87KB	Share
SPL VivaGel BV granted QIDP and Fast Track designation by US FDA
12/01/17	PRICE SENSITIVE	89.15KB	Share
SPL Starpharma receives $3.5M R&D tax incentive refund
22/12/16	PRICE SENSITIVE	94.7KB	Share
SPL Change in Director's Interest Notice - J Fairley
05/12/16		73.58KB	Share
SPL Appendix 3B
05/12/16		115.28KB	Share
SPL Change in Director's Interest Notice - R Thomas
05/12/16		74.47KB	Share
SPL 2016 AGM Results
29/11/16		100.62KB	Share
SPL AGM - Chairman address and CEO presentation
29/11/16		10.17MB	Share
SPL Starpharma signs license for VivaGel Condom in Iran
28/11/16	PRICE SENSITIVE	95.11KB	Share
SPL Starpharma to present at Bio-Europe conference
08/11/16		94.13KB	Share
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX
28/10/16	PRICE SENSITIVE	296.3KB	Share
SPL Additional Priostar Glyphosate Patent Allowed in US-SPL.AX
28/10/16	PRICE SENSITIVE	175.55KB	Share
SPL Starpharma to present at US Drug Delivery Conference-SPL.AX
26/10/16		86.37KB	Share
SPL Notice of Annual General Meeting/Proxy Form-SPL.AX
26/10/16		512.22KB	Share
SPL Starpharma to present at ASX Spotlight in Asia-SPL.AX
25/10/16		174.71KB	Share
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
17/10/16		74.34KB	Share
SPL Change in Director's Interest Notice - J Fairley-SPL.AX
13/10/16		71.85KB	Share
SPL Appendix 3B-SPL.AX
13/10/16		114.37KB	Share
SPL Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX
13/10/16	PRICE SENSITIVE	102.91KB	Share
SPL Change in Director's Interest Notice - J Fairley-SPL.AX
07/10/16		71.32KB	Share
SPL Appendix 3B-SPL.AX
07/10/16		149.9KB	Share
SPL Notification of AGM date-SPL.AX
03/10/16		92.26KB	Share
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
19/09/16		74.33KB	Share
SPL Change in substantial holding-SPL.AX
14/09/16		151.52KB	Share
SPL VivaGel condom receives regulatory approval in Canada-SPL.AX
13/09/16	PRICE SENSITIVE	924.91KB	Share
SPL Appendix 4E - Correction to NTA Backing-SPL.AX
31/08/16		193.1KB	Share
SPL Starpharma Highlights of FY2016 Presentation-SPL.AX
30/08/16		1.5MB	Share
SPL Appendix 4G - Corporate Governance Statement-SPL.AX
29/08/16		145.91KB	Share
SPL Annual report and full year financial results-SPL.AX
29/08/16	PRICE SENSITIVE	2.79MB	Share
SPL New DEP drug delivery program initiated with AstraZeneca-SPL.AX
28/07/16	PRICE SENSITIVE	81.78KB	Share
SPL Starpharma signs license for a VivaGel condom in China-SPL.AX
21/07/16	PRICE SENSITIVE	118.11KB	Share
SPL Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX
14/07/16	PRICE SENSITIVE	115.75KB	Share
SPL Change in substantial holding-SPL.AX
14/06/16		219.1KB	Share
SPL Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX
25/05/16	PRICE SENSITIVE	168.89KB	Share
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
19/05/16		73.42KB	Share
SPL Starpharma to present at ASX CEO Session-SPL.AX
17/05/16		80.32KB	Share
SPL Australian Olympic Team taking Dual Protect VivaGel Condoms,ANN-SPL.AX
16/05/16		129.83KB	Share
SPL VivaGel active against Zika virus-SPL.AX
05/05/16	PRICE SENSITIVE	97.19KB	Share
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX
28/04/16	PRICE SENSITIVE	210.3KB	Share
SPL Shareholder Update April 2016-SPL.AX
13/04/16		1.31MB	Share
SPL Starpharma to present at Bio-Europe conference-SPL.AX
05/04/16		79.83KB	Share
SPL DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX
04/04/16	PRICE SENSITIVE	173.5KB	Share
SPL Adama Licenses Starpharma's Priostar for Novel 2,4-D
17/03/16	PRICE SENSITIVE	113.63KB	Share
SPL Starpharma licences VivaGel BV to Aspen for ANZ
04/03/16	PRICE SENSITIVE	171.35KB	Share
SPL Change in substantial holding
24/02/16		189.21KB	Share
SPL Interim Report and Half-Year Financial Results
17/02/16	PRICE SENSITIVE	608.58KB	Share
SPL Targeted DEP shows sustained superior performance
02/02/16	PRICE SENSITIVE	263.74KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
28/01/16	PRICE SENSITIVE	159.74KB	Share
SPL Change in Director's Interest Notice - Z Peach
27/01/16		163.51KB	Share
SPL Change in Director's Interest Notice - P Turvey
27/01/16		162.17KB	Share
SPL Change in Director's Interest Notice - J Fairley
27/01/16		178.01KB	Share
SPL Change in Director's Interest Notice - R Thomas
27/01/16		163.94KB	Share
SPL Appendix 3B
25/01/16		153.88KB	Share
SPL Appendix 3B - SPP
22/01/16		149.44KB	Share
SPL Starpharma raises $1.9M under Share Purchase Plan
20/01/16	PRICE SENSITIVE	91.88KB	Share
SPL Change in Director's Interest Notice - R Thomas
22/12/15		163.61KB	Share
SPL Change in substantial holding
18/12/15		145.12KB	Share
SPL Share Purchase Plan Offer Documents
16/12/15		657.76KB	Share
SPL Cleansing Statement
16/12/15		289.67KB	Share
SPL Appendix 3B - Share Placement
16/12/15		258.66KB	Share
SPL Starpharma signs MOU for VivaGel condom in China
16/12/15	PRICE SENSITIVE	220.91KB	Share
SPL Change in substantial holding
15/12/15		197.85KB	Share
SPL Starpharma completes A$32 million placement
09/12/15	PRICE SENSITIVE	88.92KB	Share
SPL Trading Halt
07/12/15	PRICE SENSITIVE	285.04KB	Share
SPL Change in Director's Interest Notice - J Fairley
04/12/15		179.89KB	Share
SPL Appendix 3B
04/12/15		273.29KB	Share
SPL Second DEP candidate selected by AstraZeneca
02/12/15		79.06KB	Share
SPL Retirement of Director Peter Jenkins and Appendix 3Z
19/11/15		289.4KB	Share
SPL 2015 AGM results
19/11/15		141.22KB	Share
SPL AGM - Chair address and CEO presentation
19/11/15		1.75MB	Share
SPL DEP outperforms leading treatments in ovarian cancer model
16/11/15	PRICE SENSITIVE	302.61KB	Share
SPL Starpharma receives $3.4M R&D tax incentive
12/11/15	PRICE SENSITIVE	124.55KB	Share
SPL Starpharma to present at BioEurope conference
04/11/15		96.89KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/10/15	PRICE SENSITIVE	136.6KB	Share
SPL Shareholder Update October 2015
29/10/15		994.45KB	Share
SPL Notice of Annual General Meeting/Proxy Form
16/10/15		286.86KB	Share
SPL Additional US Patent Granted for VivaGel BV
14/10/15	PRICE SENSITIVE	122.21KB	Share
SPL Change in Director's Interest Notice - J Fairley
09/10/15		179.13KB	Share
SPL Appendix 3B
09/10/15		155.34KB	Share
SPL OTCQX Life Sciences Presentation
01/10/15		3.16MB	Share
SPL Appendix 3B
28/09/15		256.02KB	Share
SPL Change in Director's Interest Notice - R Thomas
28/09/15		71.66KB	Share
SPL EU Marketing Approval Granted for VivaGel BV
24/09/15	PRICE SENSITIVE	124.11KB	Share
SPL Date of Annual General Meeting
21/09/15		92.19KB	Share
SPL Change in Director's Interest Notice - R Hazleton
21/09/15		163.6KB	Share
SPL Change in Director's Interest Notice - P Turvey
10/09/15		227.66KB	Share
SPL Change in Director's Interest Notice - Z Peach
09/09/15		226.89KB	Share
SPL Change in Director's Interest Notice - J Fairley
09/09/15		228.52KB	Share
SPL Change in Director's Interest Notice - R Thomas
09/09/15		227.65KB	Share
SPL Drug delivery license with AstraZeneca conference call
07/09/15		91.45KB	Share
SPL Starpharma signs drug delivery license with AstraZeneca
07/09/15	PRICE SENSITIVE	142.54KB	Share
SPL Annual report and full year financial results
21/08/15	PRICE SENSITIVE	2.5MB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories